Neurodegenerative Disease Treatment: Current Options

Treatment for neurodegenerative diseases falls into two broad categories: therapies that manage symptoms and therapies that attempt to slow or halt the underlying disease process. For most conditions, including Alzheimer’s, Parkinson’s, and ALS, the drugs patients use day to day still belong to the first category. But the landscape has shifted noticeably in recent years, with the first disease-modifying treatments reaching patients for some conditions and a wave of experimental approaches targeting everything from misfolded proteins to the gut microbiome moving through clinical trials.

Symptomatic Treatments Still Carry the Load

The backbone of current neurodegenerative care is symptomatic therapy. These drugs do not change the trajectory of the disease; they compensate for what the disease disrupts. In Alzheimer’s, that generally means correcting a shortfall in the brain chemical acetylcholine. In Parkinson’s, it means replenishing dopamine. This approach has produced real, measurable improvements in patients’ daily functioning, even though it has not stopped the diseases from progressing underneath.

The limits of symptomatic treatment are well recognized. A major review in the Handbook of Clinical Neurology noted that while correcting neurotransmitter deficiencies has led to important successes in symptomatic trials, the same convergent approach has been “consistently futile” in trials aimed at neuroprotection or disease modification.¹ That tension between effective symptom relief and elusive disease modification runs through the entire field.

Alzheimer’s Disease

The Established Drugs

Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, have been the default first-line medications for Alzheimer’s for over two decades. They work by slowing the breakdown of acetylcholine, temporarily boosting levels of the neurotransmitter that Alzheimer’s depletes. Memantine takes a different tack, acting on the glutamate system to dampen excitatory signaling that can become toxic to neurons. Preclinical work has even suggested some neuroprotective properties for memantine, though it is approved and used as a symptomatic agent.²

How much do these drugs actually help? A large randomized trial published in the New England Journal of Medicine found that patients who continued donepezil scored about 1.9 points higher on a cognitive test and about 3 points better on a daily-living scale compared with those who stopped. Memantine showed a smaller but still statistically meaningful benefit on both measures.³ These are modest effects in absolute terms, but for patients and caregivers they can translate into meaningful months of preserved independence.

Anti-Amyloid Antibodies

The bigger headline in Alzheimer’s treatment is the arrival of monoclonal antibodies that target amyloid-beta, the sticky protein that accumulates in plaques throughout Alzheimer’s-affected brains. Lecanemab was the first to show both amyloid clearance and a measurable slowing of cognitive decline in a large, rigorous trial. Over 18 months, patients receiving lecanemab declined about 27% more slowly on a composite clinical scale than those on placebo, and brain amyloid burden dropped dramatically. The trade-off was not trivial: roughly a quarter of treated participants experienced infusion reactions, and about one in eight developed amyloid-related imaging abnormalities involving brain swelling or small bleeds.⁴ Donanemab, another anti-amyloid antibody, followed a similar trajectory in trials, with both drugs now being prescribed to a subset of early-stage Alzheimer’s patients.⁵

The clinical significance of these drugs remains genuinely debated. Lecanemab cleared amyloid in roughly two-thirds of participants and slowed the rate of cognitive and functional worsening, but that slowing was modest enough that some clinicians question whether individual patients can feel the difference in everyday life.⁶ They are also expensive and require regular intravenous infusions with MRI monitoring. For now, these antibodies are recommended only for people in the early stages of the disease who have confirmed amyloid pathology, not for everyone with a dementia diagnosis.

Parkinson’s Disease

Levodopa and Dopamine Agonists

Levodopa, usually combined with carbidopa to reduce side effects, remains the gold standard for Parkinson’s motor symptoms. It replaces the dopamine that dying neurons in the substantia nigra can no longer produce, and it works well, particularly in the early and middle stages. The catch is that long-term use often leads to motor fluctuations: periods when the drug’s effect wears off (“off” time) and involuntary movements called dyskinesias during “on” time.⁷

Dopamine agonists, which stimulate dopamine receptors directly, are sometimes used as an alternative or add-on, especially in younger patients. They carry a lower risk of early dyskinesia but are less potent than levodopa and come with their own side-effect profile, including impulse control problems and hallucinations. In practice, many patients end up on some combination of both.

For advanced Parkinson’s patients whose oral medications no longer provide smooth control, a continuously infused gel form of levodopa/carbidopa delivered directly into the small intestine has shown strong results. An observational study found that off time dropped by about 57%, dyskinesia duration decreased by about 28%, and painful dyskinesia was cut roughly in half.⁸ In a separate study, the majority of patients with baseline resting tremor saw it resolve completely after 12 months of intestinal gel treatment.⁹

Surgical and Device-Based Options

Deep brain stimulation has been a mainstay for Parkinson’s patients who do not respond well enough to medication for over three decades. The procedure involves implanting electrodes in specific brain targets and delivering continuous electrical pulses from a battery pack under the skin. It can meaningfully reduce tremor, rigidity, and off time, though it does not slow the disease itself and is not suitable for every patient.¹⁰

A newer option, MRI-guided focused ultrasound, offers an incisionless approach. It uses concentrated sound waves to create tiny, precise lesions in brain areas responsible for tremor, guided in real time by MRI imaging. It is best suited for tremor-dominant forms of Parkinson’s and does not require implanted hardware, which appeals to patients who are uncomfortable with the idea of brain surgery.¹¹ The trade-off is that it typically treats one side of the brain at a time, and it creates a permanent lesion rather than a reversible electrical signal.

Multiple Sclerosis

Multiple sclerosis stands out among neurodegenerative diseases because disease-modifying treatments are already well established and genuinely effective. More than a dozen approved therapies can reduce relapse rates and slow disability accumulation in relapsing forms of the disease. The most impactful recent development has been the rise of B-cell-depleting antibodies, such as ocrelizumab and ofatumumab, which target a protein called CD20 on the surface of certain immune cells. These therapies are highly effective against relapsing MS and, in the case of ocrelizumab, represent the first treatment proven to protect against disability worsening in primary progressive MS.¹²

Research into why so many different MS drugs work has turned up a striking commonality: most of them shift the balance of circulating B cells, reducing memory B cells while expanding immature or naive ones, and nudging B-cell signaling away from inflammation and toward anti-inflammatory pathways.¹³ This convergence suggests that B-cell biology is more central to MS than was appreciated for many years, and it has shaped the direction of newer therapies.

ALS and Huntington’s Disease

A Precision Turn in ALS

Amyotrophic lateral sclerosis has historically had almost nothing to offer patients beyond modest symptom management. That began to change with tofersen, an antisense oligonucleotide designed for the roughly 2% of ALS patients who carry mutations in the SOD1 gene. The drug works by reducing production of the toxic SOD1 protein. Long-term data over nearly three years showed that patients who started tofersen early had numerically less decline in physical function, respiratory capacity, and muscle strength compared with those who started later. Early-start patients had a hazard ratio of 0.52 for risk of death relative to the delayed-start group, though the confidence intervals were wide given the small patient population.¹⁴

Tofersen is not a cure, and it applies only to a small genetic subset. But it represents something genuinely new for ALS: a treatment that targets the molecular cause rather than the downstream symptoms, and that appears to change the disease’s course in at least some patients. Other genetic subtypes of ALS are now being pursued with similar precision strategies.

Huntington’s Disease

Huntington’s disease is caused by a single, well-defined genetic mutation, which in theory makes it an ideal target for gene-silencing approaches. Huntingtin-lowering therapies aim to reduce the level of the toxic mutant protein. An early-phase study of one such drug, an antisense oligonucleotide called tominersen (previously RG6042), was generally safe and well tolerated in adults with early manifest Huntington’s, and preclinical data showed that reducing mutant huntingtin was associated with decreased disease-related pathology.¹⁵ However, a subsequent larger trial was halted early due to a worsening signal, and the field is now recalibrating. The concept of lowering the harmful protein remains widely supported; the challenge has been doing so without also depleting the normal copy of huntingtin that the brain needs.

Targeting Tau and Other Misfolded Proteins

Amyloid has received most of the drug-development attention in Alzheimer’s, but tau protein, which forms tangled clumps inside neurons, correlates more tightly with cognitive decline. A growing class of tau aggregation inhibitors, both small molecules and natural compounds, are being studied for their ability to prevent tau from clumping in the first place. Some emerging compounds show dual activity against both tau and amyloid pathology, which could be especially valuable given how both proteins contribute to the disease.¹⁶

One promising experimental approach uses a peptide-based inhibitor called RI-AG03 that can suppress aggregation of multiple tau species in both lab and animal models without apparent toxicity, and it reduced neurodegeneration-related behavior in treated animals.¹⁷ In parallel, conformation-selective antibodies that recognize specific pathological shapes of tau have been shown to block the uptake of tau “seeds” into healthy neurons and reduce tau pathology in animal models of Alzheimer’s.¹⁸ None of these tau-targeting approaches have reached the market, but they represent the field’s recognition that amyloid alone does not explain the full biology of neurodegeneration.

Gene Therapy and Stem Cells

The success of a gene therapy for spinal muscular atrophy, which delivers a working copy of the defective gene through a single intravenous injection and promotes survival and motor function, has become a template for the wider neurodegenerative field. Much of the recent optimism for gene-based treatments comes from advances in viral vectors capable of spreading therapeutic genes throughout the central nervous system, along with genome-editing tools that can manipulate disease pathways in ways that were not previously possible.¹⁹

On the regenerative side, stem-cell approaches have moved beyond the proof-of-concept stage. In a landmark primate study, dopamine-producing neurons derived from induced pluripotent stem cells were transplanted into a Parkinson’s model and survived for two years, producing gradual motor improvement without the need for immune suppression because the cells came from the animal’s own body.²⁰ Human trials are now underway. A clinical effort in Japan is testing transplantation of stem-cell-derived dopamine progenitors into Parkinson’s patients, though challenges remain. The most serious concerns include the risk of tumor growth from residual undifferentiated cells and a phenomenon called graft-induced dyskinesia, where the transplanted cells produce unintended involuntary movements.²¹

Getting Drugs Past the Blood-Brain Barrier

One of the persistent frustrations in treating brain diseases is that the blood-brain barrier, a tightly sealed network of blood vessel walls, keeps most large molecules out of the brain. A drug that works beautifully in a petri dish is useless if it cannot reach its target. Three strategies are generating the most interest for solving this problem.

Focused ultrasound combined with tiny gas-filled microbubbles can temporarily open the barrier in a targeted area, allowing drugs to enter the brain locally. This approach has moved into early human trials for Alzheimer’s patients. Receptor-mediated transcytosis, which attaches drugs to molecules that naturally ferry cargo across the barrier (such as those recognized by the transferrin receptor), has also reached human testing.²² Nanoparticle carrier systems engineered to hitch a ride on these same receptors show promise in preclinical work, though they still need further validation before clinical use.²³ Recent experiments with non-spherical microbubbles coated in transferrin-receptor antibodies found that rod-shaped bubbles bound more efficiently to brain blood vessels and enhanced drug delivery compared with spherical ones, illustrating how even the geometry of the delivery vehicle matters.²⁴

Blood Tests That Could Reshape Treatment Decisions

Diagnosing and monitoring neurodegenerative diseases has traditionally required expensive brain imaging or invasive spinal taps. A blood test that could accomplish the same things would not just be convenient; it would change who gets treated and how trials are designed. The most advanced candidate is a blood marker called plasma p-tau217, which tracks a specific form of the tau protein linked to Alzheimer’s pathology. Studies have found that p-tau217 levels rise as Alzheimer’s pathology worsens, and that measuring it over time could serve as a trial endpoint, potentially cutting costs and accelerating the evaluation of new drugs.²⁵

On the diagnostic side, p-tau217 alone achieved impressively high accuracy for predicting which patients have significant tau pathology in their brains, performing nearly as well as sophisticated machine learning models that incorporated additional variables. Using this blood test as a screening step could spare more than half of patients from needing expensive tau-PET brain scans to determine whether they are candidates for anti-amyloid therapy.²⁶ For a treatment landscape where eligibility depends on confirming specific brain pathology, this kind of accessible screening tool is not a minor convenience; it is a prerequisite for making new therapies available at scale.

Neuroinflammation and Metabolic Targets

Inflammation in the brain, driven largely by immune cells called microglia, is increasingly seen as both a driver and an accelerator of neurodegeneration. A protein called TREM2, expressed on the surface of microglia, has emerged as a key regulator of this process. TREM2 influences how microglia respond to damage: in some contexts it is protective, helping clear debris and calm inflammation, while in others it may contribute to pathology. A soluble fragment of TREM2 is also being evaluated as a clinical biomarker for tracking the severity of neuroinflammation.²⁷ Therapies designed to boost or modulate TREM2 signaling are in early development, based on the logic that helping microglia function properly could slow multiple neurodegenerative diseases at once.²⁸

A separate but overlapping metabolic angle involves GLP-1 receptor agonists, the same class of drugs used for diabetes and weight loss. Preclinical studies have shown that GLP-1 receptor agonists can reduce neuroinflammation, improve mitochondrial function, and decrease the abnormal protein clumping seen in both Alzheimer’s and Parkinson’s.²⁹ Large-scale clinical trials are now testing whether these benefits translate to people. The appeal is obvious: repurposing a drug class that already has extensive safety data and manufacturing infrastructure.

Multi-Target Strategies and the Gut-Brain Connection

One of the hard-won lessons of the past two decades of neurodegenerative drug development is that single-target approaches often disappoint. Diseases like Alzheimer’s involve multiple overlapping pathological processes, and knocking down amyloid alone, or tau alone, or inflammation alone, may not be enough. Multi-target drug design aims to hit several of these pathways simultaneously, either through single molecules engineered to bind multiple targets or through carefully chosen drug combinations.³⁰ The approach makes intuitive sense but is extremely difficult to execute: optimizing a molecule for one target is hard enough, and doing so for two or three at once compounds every pharmacological challenge.

The gut microbiome has also become a serious area of therapeutic exploration. Alterations in the composition and metabolites of gut bacteria have been documented across Alzheimer’s, Parkinson’s, ALS, and Huntington’s, and the gut-brain signaling axis offers a potential route for intervention. Strategies under investigation include specialized diets, probiotics, prebiotics, microbial metabolites, antibacterials, and fecal microbiome transplantation.³¹ The evidence here is earlier-stage than for most of the other approaches discussed in this article, but the rationale is grounded in a now-substantial body of work linking gut microbial changes to brain pathology.

Exercise, Cognitive Activity, and the Concept of Reserve

No discussion of neurodegenerative treatment is complete without acknowledging the non-pharmacological side. Physical activity, particularly aerobic exercise, is associated with reduced risk of dementia in long-term studies and with preservation of brain volume and structural integrity. Cognitive activity, including training that targets working memory and other executive functions, appears to strengthen the flexibility of neural circuits. The two complement each other: physical exercise preserves the brain’s structural hardware, while cognitive engagement builds what researchers call cognitive reserve, the brain’s software-level capacity to compensate for damage.³²

Intervention studies support these observations. In a study comparing groups with different levels of physical activity, participants with the highest activity levels showed significantly better global cognitive function, even though no group had crossed into pathological decline.³³ Exercise and cognitive training are not replacements for medical treatment, but for many patients they are the most accessible tools available, they carry virtually no risk, and they may augment whatever pharmacological therapy is on board.

Cost, Access, and the Practical Reality

The new generation of disease-modifying therapies raises sharp questions about who can actually receive them. Anti-amyloid antibodies like lecanemab and donanemab require biweekly infusions at specialized centers, regular MRI monitoring, and confirmatory biomarker testing before a patient is even eligible. Cost analyses have flagged these complexities, noting that the economic models used to evaluate such treatments often do not capture the full picture, including sociodemographic differences in outcomes, the concurrent use of older symptomatic drugs, and the toll on caregivers that standard quality-of-life scales may miss.³⁴ If blood-based biomarkers like p-tau217 can reliably screen patients for eligibility without requiring PET scans and lumbar punctures, that alone would remove one of the largest bottlenecks to equitable access.

For patients living far from academic medical centers, or in countries where specialized infusion infrastructure does not exist, many of these treatments might as well not exist. The practical reality is that the global majority of people with neurodegenerative diseases still rely on generic levodopa, generic donepezil, and whatever physical therapy and social support they can access. Closing the gap between what is scientifically possible and what is broadly available remains one of the field’s defining challenges.